In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes | Zendy

Kaori Tanaka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes

Author(s) -

Kaori Tanaka

Publication year - 2000

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/46.3.465

Subject(s) - peptostreptococcus , microbiology and biotechnology , clindamycin , anaerobic bacteria , propionibacterium acnes , prevotella , antimicrobial , prevotella intermedia , clarithromycin , piperacillin , metronidazole , biology , bacteria , chemistry , antibiotics , porphyromonas gingivalis , pseudomonas aeruginosa , genetics

The in vitro activity of SCH27899, a novel oligosaccharide antimicrobial agent, was compared with those of representatives of six classes of antimicrobial agents (piperacillin, clarithromycin, clindamycin, vancomycin, sitafloxacin and metronidazole) against clinical isolates of anaerobic bacteria and Propionibacterium acnes. Against Peptostreptococcus: spp. and Clostridium difficile, SCH27899 was the most potent (MIC(90) < 0.125 mg/L) of the agents examined. Besides these Gram-positive anaerobes, SCH27899 showed a moderate level of activity against Prevotella bivia, Prevotella intermedia and Porphyromonas: spp. (MIC(90)< or = 4 mg/L).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research